A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients.

被引：0
|
作者：
Si, L. [1 ]
Mao, L. L. [1 ]
Chi, Z. H. [1 ]
Cui, C. L. [1 ]
Sheng, X. N. [1 ]
Li, S. M. [1 ]
Tang, B. X. [1 ]
Guo, J. [1 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.8544
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8544
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma
    Gogas, H.
    Dafni, U.
    Bafaloukos, D.
    Polyzos, A.
    Kokkalis, G.
    Kalofonos, H. P.
    Fountzilas, G.
    Skarlos, D.
    Tsoutsos, D.
    Pectasides, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
    Pectasides, Dimitrios
    Dafni, Urania
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis
    Polyzos, Aristidis
    Tsoutsos, Dimosthenis
    Kalofonos, Haralambos
    Fountzilas, George
    Panagiotou, Petros
    Kokkalis, George
    Papadopoulos, Othon
    Castana, Ourania
    Papadopoulos, Stefanos
    Stavrinidis, Elias
    Vourli, Georgia
    Ioannovich, John
    Gogas, Helen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
  • [3] A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
    Mao, Lili
    Si, Lu
    Chi, Zhihong
    Cui, Chuanliang
    Sheng, Xinan
    Li, Siming
    Tang, Bixia
    Guo, Jun
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1498 - 1503
  • [4] Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
    Jonasch, E
    Kumar, UN
    Linette, GP
    Hodi, FS
    Soiffer, RJ
    Ryan, BF
    Sober, AJ
    Mihm, MC
    Tsao, H
    Langley, RG
    Cosimi, BA
    Gadd, MA
    Tanabe, KK
    Souba, W
    Haynes, HA
    Barnhill, R
    Osteen, R
    Haluska, FG
    [J]. CANCER JOURNAL, 2000, 6 (03): : 139 - 145
  • [5] Adjuvant interferon alfa-2b for high-risk melanoma
    Retsas, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1968 - 1968
  • [6] Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b
    Fluck, M
    Kamanabrou, D
    Lippold, A
    Reitz, M
    Atzpodien, J
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (03) : 280 - 289
  • [7] Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma
    Lian, Bin
    Mao, Li Li
    Cui, Chuan Liang
    Chi, Zhi Hong
    Si, Lu
    Sheng, Xi Nan
    Li, Si Ming
    Tang, Bi Xia
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Tolerability of a adjuvant high-dose interferon alfa-2b:: 1 month versus 1 year -: A hellenic cooperative oncology group study
    Gogas, H
    Bafaloukos, D
    Ioannovich, J
    Skarlos, D
    Polyzos, A
    Fountzilas, G
    Kalofonos, HP
    Aravantinos, G
    Tsoutsos, D
    Panagiotou, P
    Frangia, K
    Petrakopoulou, T
    Pectasides, D
    [J]. ANTICANCER RESEARCH, 2004, 24 (3B) : 1947 - 1952
  • [9] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma
    Agarwala, Sanjiv S.
    Gray, Robert J.
    Wong, Michael K. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E82 - E83
  • [10] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma Reply
    Pectasides, Dimitrios
    Dafni, Urania
    Gogas, Helen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E84 - E84
12345